Migraine

This article is about the disorder. For other uses, see Migraine (disambiguation).

Migraine
Woman during a migraine attack
Specialty	Neurology
Symptoms	Headaches coupled with sensory disturbances such as nausea, sensitivity to light, sound, and smell
Usual onset	Often around puberty
Duration	Recurrent, long term
Causes	Environmental and genetic
Risk factors	Family history, female sex
Differential diagnosis	Subarachnoid hemorrhage, venous thrombosis, idiopathic intracranial hypertension, brain tumor, tension headache, sinusitis, cluster headache
Prevention	Propranolol, amitriptyline, topiramate, gepants
Medication	Ibuprofen, paracetamol (acetaminophen), triptans, gepants
Prevalence	~14%

Migraine ^[a] is a neurological disorder that causes moderate-to-severe headaches. The pain usually affects one side of the head and is generally associated with nausea, light sensitivity and sound sensitivity. ^{[3] [4]} Other symptoms may include dizziness, vomiting, ^[3] and difficulty thinking. ^[5] In some cases, a migraine attack begins with an aura, a period of sensory disturbance. ^[4]

Migraine attacks vary between individuals. Some people experience occasional attacks, while others develop chronic migraine with frequent headaches. ^{[6] [7]} Migraine frequency can increase over time. In some cases, frequent use of pain medication for headaches can make migraines worse and lead to medication overuse headache. ^[8] An attack can be triggered by various stressors, such as lack of sleep, skipped meals or hormonal fluctuations. ^[9]

Migraine is believed to result from a combination of genetic, environmental, and neurological factors that affect the activity of nerve cells and chemical signals in the brain. Migraine attacks are theorized to occur when the brain exceeds an individual sensitivity threshold. Migraine attacks have multiple phases. The initial phase of a migraine attack can start 48 hours before the main headache phase and may cause early warning symptoms. The subsequent pain phase of a migraine attack may be linked to increased activity in the pain pathway from the trigeminal nerve to the brainstem. Release of a signalling molecule CGRP increases blood flow and the transmission of pain signals. ^{[10] [11] [9]}

A migraine management plan often includes lifestyle modifications to cope with migraine triggers and reduce the impact of co-occurring conditions. ^{[12] [13]} Lifestyle changes that may prevent migraines include stress management, improving sleep habits, eating regularly, and exercise. ^{[12] [14] [15]} Treatment for acute mild to moderate attacks begins with over-the-counter pain relievers such as ibuprofen and paracetamol. ^[16] Triptans are recommended as a first-line therapy for moderate to severe attacks. ^[16] The approval of CGRP inhibitors (gepants) is seen as a major advance in migraine treatment. ^{[17] [18]} Anti-nausea medications are used for migraine-related nausea. ^[16] Ergotamines may be used by those experiencing headaches that do not respond to other medications. ^{[19] [16]} Several medications can help prevent migraines. These include CGRP inhibitors, but also beta blockers, anticonvulsants and certain antidepressants. ^{[20] [17] [21] [22]}

Approximately 14% (1.16 billion) of people worldwide are affected by migraine, ^[23] making it the third most disabling condition affecting the nervous system ^[24] and one of the most common causes of disability. ^[25] Beginning at puberty, women experience more and longer migraines, and higher disability related to migraines. ^{[26] [27] [28]} Migraines often start occuring after a girl's first period, with increased frequency over time, peaking during perimenopause and tending to decrease following menopause. ^[29] From age 30 to 50, up to four times as many women experience migraine attacks as men. ^[30]

Signs and symptoms

Migraine typically presents as recurrent, mostly one-sided, pulsating headaches, along with heightened sensitivity to light, sound, and other sensory stimuli. The severity of the pain, duration of the headache, and frequency of attacks are variable. Symptoms may last for hours or days, seriously affecting quality of life. ^{[31] [32]}

Migraine attacks can be described in terms of four stages or phases, which may not all be experienced. ^{[31] [33]} In addition, the period between migraine attacks is sometimes referred to as the interictal phase. ^[34]

• The premonitory phase or prodrome, generally defined as the 48 hours preceding the pain phase. ^[31]
• Aura, ^[31] reversible neurological disturbances (often visual) lasting 5–60 min, generally near onset of the pain phase. ^[35] These are reported by about 30% of migraineurs. ^{[36] [34]}
• The pain phase, also known as the headache phase. ^[31]
• The postdrome, effects following the end of the pain phase of an attack. ^[31]

About 30% of people living with migraine experience episodes with aura. ^{[36] [34]} Women are more likely than men to experience migraine without aura. ^{[37] [26] [27]} A migraine attack lasting longer than 72 hours despite treatment is referred to as status migrainosus. This can lead to complications like dehydration and electrolyte imbalances, and may require emergency room or hospital-level care. ^{[38] [39] [40]}

Migraine is associated with neuropsychiatric disorders including major depression, bipolar disorder, anxiety disorders, obsessive–compulsive disorder, and sleep disorders. Shared neurobiological mechanisms may underlie multiple conditions. ^[41] Co-occurrence with specific psychiatric disorders differs for those experiencing migraine with and without aura. ^[42]

Prodrome phase

The prodrome phase of migraine is generally defined as the 48 hours preceding the pain or aura phases of an attack. ^[43] Estimates of the occurrence of premonitory or prodromal symptoms in people with migraine vary widely. Around 29% of people with migraine in population-based studies report at least one premonitory symptom, while around 66% of people in clinic populations report premonitory symptoms. ^[43] These symptoms may include a wide variety of phenomena, including altered mood, irritability, depression or euphoria, fatigue, craving for certain food(s), difficulty speaking or reading, yawning, stiff muscles (especially in the neck), constipation or diarrhea, and sensitivity to smells or noise. Premonitory symptoms may occur with both migraine without aura and migraine with aura. ^{[44] [45]} Neuroimaging indicates that changes in activity in the limbic system and hypothalamus are associated with prodromal symptoms in migraine. ^{[10] [11]}

Aura phase

Aura is a transient neurological event that can occur over 5–60 minutes, generally just prior to the onset of headache pain. ^{[26] [46]} Symptoms can be visual, sensory or motoric in nature, but visual effects occur most frequently, in as many as 99% of cases of migraine with aura. In rare cases known as persistent aura, aura symptoms may remain after 60 minutes. ^[47]

Visual disturbances often consist of a scintillating scotoma (an area of partial alteration in the field of vision, which flickers and may interfere with a person's ability to read or drive). These typically start near the center of vision and then spread out to the sides with zigzagging lines, which have been described as looking like fortifications or walls of a castle. Usually, the lines are in black and white, but some people also see colored lines. Some people lose part of their field of vision, while others experience blurring. ^{[48] [49] [50]}

Sensory auras are the second most common type; they occur in 30–40% of people with auras. Often, a feeling of pins-and-needles begins on one side in the hand and arm and spreads to the nose–mouth area on the same side. Numbness usually occurs after the tingling has passed with a loss of position sense. Other symptoms of the aura phase can include speech or language disturbances, world spinning, and, less commonly, motor problems. Motor symptoms indicate that this is a hemiplegic migraine, and weakness often lasts longer than one hour unlike other auras. ^[51]

Pain phase

Classically the headache is unilateral, throbbing, and moderate to severe in intensity. ^[31] The feeling of pulsating pain is not in phase with the pulse. ^[52] In around 40% of cases, the pain may be bilateral, affecting both sides of the head. ^[53] The pain usually lasts 4 to 72 hours in adults. ^[53] Pediatric and adolescent migraines differ from adult presentations, more often involving bilateral headaches with shorter duration. ^[54]

Pain is frequently accompanied by nausea, vomiting, sensitivity to light, sensitivity to sound, sensitivity to smells, fatigue, and irritability. Many prefer a dark and quiet environment, and seek to avoid stimuli to which they are sensitive. Nausea occurs in almost 90% of people, and vomiting occurs in about one-third. ^{[39] [21] [55]} Other symptoms may include blurred vision, ^[50] sino-nasal symptoms such as nasal stuffiness, ^[56] diarrhea, ^[57] neck pain, ^[58] and swelling or tenderness of the scalp. ^[59] In rare cases of migraine with brainstem aura (basilar migraine), neurological symptoms related to the brain stem may affect both sides of the body, including a sense of the world spinning, light-headedness, and confusion. ^[60]

During the pain phase, motion and physical activity may increase pain. Migraineurs are likely to decrease physical activity during this time. ^[61] However, the effects of physical activity on migraine are complex, and regular exercise on an on-going basis may have a preventive effect and decrease frequency of migraine attacks. ^{[62] [63]}

Silent migraine

Aura may occur without a subsequent headache, ^[64] which is called a typical aura without headache, or commonly as a "silent migraine". ^{[65] [66]} Symptoms such as visual disturbance, vision loss, alterations in color perception, and sensitivity to light, sound, and odors may still be debilitating in the absence of pain. ^[31]

Postdrome

The migraine postdrome, sometimes referred to as the "migraine hangover", is the constellation of symptoms occurring after the acute headache has ceased. The International Classification of Headache Disorders (ICHD-3) defines this as the 48 hours after the pain ceases. Common symptoms include tiredness, difficulty concentrating, mood changes, and thirst. ^[67] Other symptoms reported include dizziness and euphoria. ^[3]

Causes

Migraine is believed to result from a mix of genetic, environmental, and neurological factors. ^[10] Migraine runs in families, with heritability estimates of 34–64%, but this rarely reflects a single gene defect. Rather, a variety of genetic factors may relate to neuronal, vascular and other systems, and create genetic susceptibility. ^[68] Migraine often occurs with conditions such as depression, anxiety, and bipolar disorder, which may have a bidirectional relationship (either one can worsen the other). It is likely that shared genetic and neurobiological mechanisms contribute to risk factors that underlie multiple conditions. ^{[69] [70]}

Intracranial cavernous sinus: a potential site where dilation of cerebral vessels can compress multiple cranial nerves.

Genetics

Main article: Genetics of migraine

Studies of twin adults indicate a 0.36 to 0.48 genetic influence on the likelihood of developing migraine. However, few studies examine non-European populations, or distinguish between migraine with aura and migraine without aura. ^[71] It is clear from family and populations studies that migraine is a complex disorder, where numerous genetic risk variants exist, and where each variant increases the risk of migraine marginally. ^{[72] [73]} It is also known that having several of these risk variants increases the risk by a small to moderate amount. ^[68]

Single gene disorders that result in migraine are rare. One of these is known as familial hemiplegic migraine, a type of migraine with aura, which is inherited in an autosomal dominant fashion. Three main genes have been shown to be involved in familial hemiplegic migraine via ion transport: CACNA1A, ATP1A2, and SCN1A. ^[68]

Another genetic disorder that has been associated with migraine is CADASIL syndrome or cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Despite some similarities in symptoms, ICHD-3 recommends that this be diagnosed "headache attributed to CADASIL" (code 6.8.1) rather than migraine with aura (MA) or migraine without aura (MO) (codes 1.1 and 1.2). ^[74] The TRPM8 gene, which codes for a cation channel, has been linked to migraine. ^{[75] [76]} One meta-analysis found a protective effect from angiotensin converting enzyme polymorphisms on migraine. ^{[77] [78]}

The common forms of migraine are polygenetic, where common variants of numerous genes contribute to the predisposition for migraine. ^[68] These genes can be placed in three categories: increasing the risk of migraine in general, specifically migraine with aura, or migraine without aura. ^{[79] [80]} Three of these genes, CALCA , CALCB , and HTR1F are already target for migraine specific treatments. Five genes are specific risk to migraine with aura, PALMD , ABO , LRRK2, CACNA1A and PRRT2, and 13 genes are specific to migraine without aura. Using the accumulated genetic risk of the common variations, into a so-called polygenetic risk, it is possible to assess e.g. the treatment response to triptans. ^{[81] [82]}

Triggers

A migraine trigger reduces the threshold at which a migraine attack occurs in someone who is predisposed to migraine. ^{[83] [44] [17] [84]} Categories of hypothesized migraine triggers include emotion, nutrition, sleep disturbance, hormones, weather, sensory overstimulation and strenuous exercise. ^[85] Migraine triggers may be classified as internal, modifying the body's homeostasis (e.g. hormonal variability, stress, sleep disturbance, fasting) or external, originating outside the body and influencing the perception of sensory signals (e.g. temperature fluctuations, noises, and odors). In some cases, factors reported as triggers (e.g. sensory sensitivities, food cravings and mood change) may be more appropriately considered as premonitory symptoms resulting from changes in brain activity during the prodromal phase of migraine. ^{[44] [17] [83] [84]} Determining whether and when something acts as a true causal trigger, and when it is a symptom of already-occurring changes, is an ongoing area of study. ^[44]

Studies of the brain's structure and function indicate that brain activity changes during the 48 (or even 72) hours before the pain phase of migraine. During this initial phase of a migraine attack, people may report prodromal/premonitory symptoms (PSs) such as fatigue, yawning, difficulty concentrating, mood changes, dizziness, neck pain, light sensitivity, food cravings, and nausea. Such symptoms may continue into the pain phase and postdrome. ^[44] Some studies suggest that PSs may be linked to activity in particular neuroanatomical pathways and areas of the brain. Yawning, food cravings, homeostatic regulation, and sleep disturbance may be linked to activation in the hypothalamus. Other PSs, such as neck pain and nausea, may be related to activity in the brainstem. ^[44] The stimuli that are found disturbing vary from person to person. ^[86] Those experiencing PSs can sometimes correctly predict an oncoming attack. ^[44]

The extent to which a possible trigger has an actual causal connection with headache onset is uncertain in most cases, and some relationships may be bidirectional. ^{[69] [70]} However, there are strong associations between migraine and hormonal changes, stress, quality of sleep, and fasting. It has been theorized that these "catalyst triggers" may act by increasing activity in the hypothalamus or trigeminal system and exceeding the brain's migraine threshold. ^[44] Lifestyle changes that help to maintain bodily homeostasis, such as regular sleep, managing of stress, and eating regularly, can be helpful interventions. ^[87] Whether a possible trigger is a cause or an early symptom of a migraine attack, it may help to manage exposure to sensory stimuli such as smells, lights, sound or touch. ^[86]

Hormonal changes

From puberty onwards, women experience migraine attacks at greater rates and with greater severity of symptoms than men. ^[26] Women are more likely than men to experience migraine without aura. A population-based study in Denmark suggests that sex differences in rate and severity of migraine attacks almost exclusively reflect the incidence of migraine without aura (11% in females and 3.59% in males). In comparison, sex differences were not significant in migraine with aura (1.72% in females and 1.58% in males). ^[88]

This divergence in patterns of migraine attacks in men and women is a result of changes in sex hormones. ^[26] The incidence of attacks of migraine without aura is strongly related to hormonal fluctuations in estrogen, which varies monthly and across a woman's lifespan. ^[89] Migraine episodes are more likely to occur immediately before and during menstruation, possibly due to the drop in estrogen levels prior to the menstrual period. ^[90]

Occurrence of migraine without aura displays an age-related pattern. ^{[26] [37]} First onset of migraine is often reported around the first menstrual cycle, and prevalence increases from early adulthood throughout the childbearing years. ^[88] Incidence and severity of migraine without aura peaks between ages 35 and 50. ^{[37] [29]} Attacks may worsen during perimenopause due to irregular periods and fluctuating estrogen levels. The first onset of migraine may occur during perimenopause. ^{[30] [29]} Following menopause, estrogen levels tend to stabilize at a lower rate, and migraine frequency and severity are likely to decrease. ^{[26] [29]}

Migraine episodes tend to diminish during the 2nd and 3rd trimesters of pregnancy, when elevated estrogen levels are stable. They are likely to return following the abrupt drop in estrogen levels after childbirth. ^[26]

Relationships between oral contraceptive use and migraine are less clear, and may differ depending on migraine type, age, and characteristics of the menstrual cycle. In some cases, use of oral contraceptives or hormone replacement therapy can help to stabilize estrogen levels and prevent migraines, ^[90] while stopping hormonal contraceptives suddenly may be associated with increased attacks. ^[26]

Women who experience migraine with aura differ from women who experience migraine without aura in onset, symptoms and recommended treatments. Women who perceive aura are more likely to have experienced the first onset of migraine before menarche. ^[29] For women who experience migraine with aura, migraines are less likely to improve during pregnancy, and use of oral contraceptives is more likely to worsen attacks. Women with migraine with aura who use combined hormonal contraceptives have a higher risk of ischemic stroke. ^[26]

Stress

The headache trigger that people are most aware of is stress, ranking first in reports for men, and second to hormonal factors for women. ^{[83] [14]} Best practices for psychologically addressing stress as a possible migraine trigger include relaxation therapy, biofeedback, and cognitive behavioral therapy (CBT). ^[91] Activities such as relaxation therapy are more likely to be effective when used as a routine part of daily life or to address incidents of stress, rather than during the pain phase of a migraine attack. ^[92]

Sleep

Migraineurs report a variety of sleep-related issues as possible triggers. These include undersleeping, irregular sleep, frequent night-time waking, and oversleeping. Those who experience chronic migraine may be less likely to maintain consistent sleep habits than those who experience episodic migraines. ^[93] Jet-lag, shift work, and other disruptions of circadian rhythms may increase migraines. ^{[94] [95] [96]} Changes in migraine frequency have been reported in relation to changes between daylight savings time and standard time. ^[97]

Sleep habits have been shown to be negatively affected by factors such as air quality and exposure to ambient and indoor pollutants. ^[98] A nationwide study of household fuel use in China found that those using solid fuel rather than clean fuel were more likely to develop migraines; those who switched from solid fuels to clean fuels showed a lower risk of migraines. However, those who used solid fuel but reported good sleep duration were not at a significantly higher risk for migraines, suggesting that sleep played a protective role. ^[99] Sleep hygiene improvements and maintaining a consistent sleep schedule are among the most frequently recommended migraine management techniques. ^{[100] [15] [101] [102]}

Diet

Fasting or missed meals are a commonly perceived trigger for migraines, and dietary modifications are a frequent management technique. ^[93] Missing meals like breakfast can reduce brain glucose levels, leading to hypoglycemia and triggering the release of stress hormones like cortisol and adrenaline, which can affect migraines. Irregular meals are particularly strong predictors of attacks for those experiencing chronic migraines. Eating balanced meals at consistent times and hydrating well can help to prevent migraines and lessen migraine symptoms. ^[103]

A wide variety of specific foods and drinks have been reported as possible triggers, including alcohol, coffee, chocolate, cheese, nuts, citrus fruits, fatty foods, processed meats, monosodium glutamate, and aspartame. ^[103] Mechanisms of action have been proposed for some of the commonly reported foods and drinks, such as red and white wine, hot dogs, and chocolate. ^[83] Tyramine, which is naturally present in alcoholic beverages, most cheeses, processed meats, and other foods may trigger migraine symptoms in some individuals. ^{[104] [105]} Tyramine is also present at low levels in chocolate. ^[106] MSG has been reported as a trigger for migraine in some individuals, but whether or not there is a causative relationship continues to be debated. ^[107]

People may experience food cravings as a result of changes in brain activity during the prodromal phase of migraine. Reports that foods such as chocolate are triggers may actually reflect a increased desire for such foods as an early symptom of migraine attacks. ^{[108] [44]}

Sensory sensitivity

Sensitivity to light (photophobia), sensitivity to sound (phonophobia), and sensitivity to smells (osmophobia) are often reported as migraine triggers. Some migraineurs may also report sensitivity to touch (allodynia). ^{[21] [55]} Neuroimaging and neurophysiological studies show changes in sensory thresholds relating to sensitivity to light, sound and smell and to pain perception. ^{[44] [109]} Patient reports of sensitivity triggers may be early symptoms in the premonitory phase of a migraine attack. ^[110] People often deal with migraine attacks by seeking a dark and quiet space, and avoiding further sensory stimulation including movement, light, sounds, touch or smells. ^[55]

Light

Sensitivity to light is a common symptom in migraine. Discomfort is associated with four categories of stimulation: bright light, flickering light, pattern, and color. While retinal mechanisms also may be involved, cortical mechanisms are increasingly seen as explaining discomfort from all four types of visual stimulation. ^[111]

People have been shown to have different thresholds for discomfort from stimuli. During migraine, stimulation can provoke a hyper-excitable cortical response involving specific subsets of neurons. Thresholds at which a response occurs and the size of the response that occurs may both be involved. For example, those with a more sensitive discomfort glare threshold have been shown to display greater activity in the cunei, lingual gyri and superior parietal lobules in response to peripheral lights. Photophobia may reflect individual differences in homeostatic response to stimuli, in which cortical hyper-excitability is further aggravated by visual stimulation. ^[111] Those who are less sensitive to light may better reduce discomfort and avoid over-stimulation. ^{[112] [111]} It has been suggested that migraineurs may experience dysfunction in inhibitory mechanisms, have difficulty habituating to ongoing stimuli, and even become sensitized to such stimuli. ^[113]

Strategies for reducing discomfort may include staying in a darkened room, wearing sunglasses or hats to avoid direct sunlight and minimize glare, using fluorescent light filters to soften and diffuse light and reduce flicker, ^[12] using green lights in preference to other colors, ^[114] and using anti-glare filters with computers. Evaluating the ergonomics of workspaces and using suitable chairs and proper posture while working, may also be helpful. ^[12]

Sound

Migraineurs frequently report hypersensitivity to sound. Research indicates that they may have lower hearing thresholds ^[115] and lower thresholds of discomfort for sounds than non-migraineurs generally, not just during migraine attacks. ^[116] Migraineurs also have lower hearing thresholds than usual while they are experiencing headaches. Lower hearing threshold correlates with headache frequency, and with frequency of auditory, visual, and tactile triggers. Phonophobia in migraineurs correlates with higher brainstem neuronal excitability. ^{[115] [117]} There is some evidence suggesting that migraineurs experience an increase or potentiation in response to blocks of sound, rather than habituation. ^[55]

Smell

Migraineurs may report increased aversion to a smell that would not be unpleasant normally, heightened awareness of a smell, or other olfaction-related symptoms. ^{[118] [86]} This is a possible diagnostic marker of migraine, distinguishing it from other types of headaches. ^[119] It is more often observed in people with a longer history of migraines and greater migraine-related impairment. This may suggest that sensitivity to stimuli increases over time. ^[120] Migraineurs who experience scent-related symptoms are more likely to experience insomnia, depression, fatigue and neuropathic pain, and to report lower quality of life than those without osmophobia. ^[121]

The brain processes smell through the olfactory, trigeminal, and pheromone systems. There is evidence that different odors may activate different brain regions. Reported trigger smells have been grouped into six general categories of products: oil derivatives and others; fetid odor; cooking; shampoos and conditioners; cleaning products; and perfumes, insecticides, and rose. ^[110] Perfumes were the smells most frequently reported in connection with migraine attacks. ^{[110] [122] [123]} Those with chronic migraines seem more likely than those with episodic migraines to be sensitive to floral scents. Strategies for reducing scent exposure include using fragrance-free products, improving ventilation and air quality, wearing masks, and using air cleaners. ^{[110] [86]}

Weather

Migraines have been reported to be triggered by changes in weather conditions such as temperature, ambient pressure, and humidity, but studies have shown mixed results. ^{[124] [125] [126] [83]}

Mechanism

Migraine is a complex neurovascular pain disorder involving blood vessels, neurons, and cerebrospinal fluid within the meninges, the brain's protective layers. The areas involved are sometimes referred to as the trigeminovascular system. The trigeminal nerve, located within the dura mater, carries sensory information about pain, touch, heat and cold from the face to the brain. The hypothalamus receives input from the trigeminal nerve and can modulate trigeminal nerve activity. ^{[127] [128] [129]} Migraine patients appear to experience impairments in cortical habituation, a process which would normally decrease cortical responses to repetitive sensory stimuli. ^{[130] [131]}

Initiation of a migraine attack may begin with disruption in the hypothalamus and limbic system. ^{[127] [128] [129]} Gradually increasing hypothalamic activity has been observed in the period leading up to a migraine attack, followed by a disruption or collapse of hypothalamic connectivity to the limbic system during an attack. ^[132] Disruption of the connection between the hypothalamus and limbic system may increase activity in the pain pathway from the trigeminal nerve to the brain, resulting in a migraine attack. ^{[127] [128] [129]}

The meninges, particularly the dura mater, are rich in pain-sensitive nerve endings. Sensory information travels along trigeminal nerve fibers to cell bodies located within the trigeminal ganglion. Axons of the trigeminal ganglion (TG) neurons enter the brainstem and travel to the trigeminal nucleus caudalis (TNC). ^{[133] [129] [134]}

The activity of calcitonin gene-related peptide (CGRP) in the meninges is linked to migraine. ^[11] CGRP is released from both the trigeminal ganglion (TG) and the trigeminal nucleus caudalis (TNC) in response to trigeminal nerve activation. CGRP activates receptors on meningeal blood vessels, causing dilation and changes in blood flow. CGRP also activates specialized nerve endings in the dura mater (nociceptors) that transmit pain signals to the central nervous system. Increased neuronal activity in the trigeminal pain pathway reaches higher cortical pain regions via the brainstem, midbrain, and thalamus. ^{[127] [129]}

Stimulation of the trigeminal nerve may result in the release of neuropeptides such as CGRP from nerve endings, release of inflammatory mediators from mast cells, vasodilation of cerebral and dural blood vessels, neurogenic inflammation, and the transmission of pain signals via nerves in the meninges. ^{[11] [135]} Cerebrospinal fluid may play a role in migraine by conveying signals from the brain to overlying pain-sensitive meningeal tissues, including the dura mater. ^[11]

Animation of cortical spreading depression

Mechanisms in migraine patients with and without aura differ, and it is recommended that these subtypes of migraine be treated separately. ^{[36] [34] [42]} The experience of aura in migraine is associated with cortical spreading depression (CSD) at the onset of a migraine attack. In cortical spreading depression, a wave of depolarization propagates across the cerebral cortex, followed by suppression of spontaneous neuronal activity. Physiologically, CSD involves an influx of sodium and calcium ions in concentrations that overwhelm the cell membrane's transport capability. Dysregulation of electrolyte concentration and disruption of homeostasis then spread to other cortical regions. ^{[136] [137]}

Incidence of migraines may increase over time, evolving from episodic migraine to chronic migraine. Overuse of acute pain medications may hasten this process of chronification, and is a risk factor in developing medication overuse headache. ^{[138] [139] [140]}

Diagnosis

The diagnosis of a migraine is based on signs and symptoms. ^[32] A headache calendar is a useful diagnostic tool for tracking the date, duration, and symptoms of headaches. Migraine can be classified according to whether the patient experiences an aura (MA) or not (MO) and frequency of headaches (episodic or chronic). ^[21] According to the ICHD-3, migraine diagnosis is primarily clinical and is based on identifying characteristic patterns of headache features and associated symptoms rather than laboratory or imaging findings ^[141] Neuroimaging tests are not necessary to diagnose migraine, but may be used to find other causes of headaches in those whose examination and history do not confirm a migraine diagnosis. ^[142] The American Headache Society's evidence-based guideline recommends neuroimaging only when "red-flag" symptoms or abnormal neurological findings are present, noting that routine imaging is unnecessary for patients who already meet clinical criteria for migraine. ^[143] It is believed that a substantial number of people with the condition remain undiagnosed. ^[32]

The diagnosis of migraine without aura, according to the International Headache Society, can be made according to the "5, 4, 3, 2, 1 criteria", which is as follows: ^[33]

• Five or more attacks – for migraine with aura, two attacks are sufficient for diagnosis.
• Four hours to three days in duration
• Two or more of the following:
  • Unilateral (affecting one side of the head)
  • Pulsating
  • Moderate or severe pain intensity
  • Worsened by or causing avoidance of routine physical activity
• One or more of the following:
  • Nausea and/or vomiting
  • Sensitivity to both light (photophobia) and sound (phonophobia)

If someone experiences two of the following: photophobia, nausea, or inability to work or study for a day, the diagnosis is more likely. ^[144] In those with four out of five of the following: pulsating headache, duration of 4–72 hours, pain on one side of the head, nausea, or symptoms that interfere with the person's life, the probability that this is a migraine attack is 92%. ^[145] In those with fewer than three of these symptoms, the probability is 17%. ^[145]

Classification

Main article: ICHD classification and diagnosis of migraine

Migraine was first comprehensively classified in 1988, when the International Headache Society (IHS) began its classification of headache disorders. ^[146] The IHS updated its classification of headaches in 2004. ^[33] A third version was published in 2018. ^[147] According to this classification, migraine is a primary headache disorder along with tension-type headaches and cluster headaches. ^[148]

Migraine is divided into six subclasses (some of which include further subdivisions): ^[149]

• Migraine without aura, or "common migraine", involves migraine headaches that are not accompanied by aura.
• Migraine with aura, or "classic migraine", usually involves migraine headaches accompanied by aura. Less commonly, aura can occur without a headache or with a nonmigraine headache.
  • Subtype of migraine with aura: hemiplegic migraine and sporadic hemiplegic migraine, in which a person has migraine with aura and with accompanying motor weakness. If a close relative has had the same condition, it is called "familial"; otherwise, it is called "sporadic".
  • Subtype of migraine with aura: basilar-type migraine, where a headache and aura are accompanied by difficulty speaking, world spinning, ringing in ears, or several other brainstem-related symptoms, but not motor weakness. This type was initially believed to be due to spasms of the basilar artery, the artery that supplies the brainstem. Now that this mechanism is not believed to be primary, the symptomatic term migraine with brainstem aura (MBA) is preferred. ^[60] Retinal migraine (which is distinct from visual or optical migraine) involves migraine headaches accompanied by visual disturbances or even temporary blindness in one eye.
• Childhood periodic syndromes that are commonly precursors of migraine include cyclical vomiting (occasional intense periods of vomiting), abdominal migraine (abdominal pain, usually accompanied by nausea), and benign paroxysmal vertigo of childhood (occasional attacks of vertigo).
• Complications of migraine describe migraine headaches and/or auras that are unusually long or unusually frequent, or associated with a seizure or brain lesion.
• Probable migraine describes conditions that have some characteristics of migraine, but where there is not enough evidence to diagnose it as migraine with certainty.
• Chronic migraine is defined as headaches occurring on at least 15 days per month for more than three months, with at least eight days per month fulfilling criteria for migraine. ^[150]

Abdominal migraine

Abdominal migraine is most frequently diagnosed in children, but occasionally in adults. Diagnostic criteria for abdominal migraine are outlined by both the Rome IV and ICHD III classification systems. Criteria include repeated, acute, paroxysmal attacks of abdominal pain that may be associated with nausea and vomiting. Attacks last for at least 1 hour and interfere with normal life. Average attack duration has been reported as 17 hours. Abdominal migraine often occurs in people with either a personal or family history of typical migraine, and children may develop typical migraine later in life. Abdominal migraine, migraine, and cyclical vomiting syndrome share common symptoms. ^[151]

Differential diagnosis

Pain distribution of tension, migraine and cluster headaches

Other conditions that can cause similar symptoms to a migraine headache include temporal arteritis, cluster headaches, acute glaucoma, meningitis and subarachnoid hemorrhage. ^[145] Temporal arteritis typically occurs in people over 50 years old and presents with tenderness over the temple. Cluster headache presents with one-sided nose stuffiness, tears and severe pain around the eyes. Acute glaucoma is associated with vision problems. Meningitis associated with fever. Subarachnoid hemorrhage is associated with a very fast onset. ^[145] Tension headaches typically occur on both sides, are not pounding, and are less disabling. ^[145]

Those with stable headaches that meet criteria for migraine should not receive neuroimaging to look for other intracranial disease. ^[142]

Management

Main article: Management of migraine

Management of migraine includes both prevention of migraine attacks and acute treatment. Preventive (prophylactic) treatment can be given in the absence of a headache to reduce the frequency and severity of future attacks. Acute (abortive) treatment attempts to diminish or reverse the progression of a headache that has already started. Measures for reducing and avoiding triggers may also be beneficial. ^[152] Headache tracking, using a headache diary or smartphone app, is a standard self-management tool used to monitor migraineurs' frequency of headache occurrence, associated symptoms or triggers, and effects of treatments. ^[153]

Prevention

A migraine management plan often includes lifestyle modifications to cope with migraine triggers and reduce the impact of comorbidities. ^{[12] [93] [154]} Recommended lifestyle modifications promote maintaining a consistent lifestyle, through regular sleep patterns, ^{[15] [101] [102]} regular eating, staying hydrated, ^[155] managing stress, ^[14] engaging in moderate exercise, and maintaining a healthy body weight. ^{[156] [12] [93]} Avoiding dietary triggers and caffeine overuse may also be recommended lifestyle modifications. ^[87] Data suggests that sleep modification may be particularly helpful in reducing migraine frequency for adults with chronic migraines. ^[157]

Behavioral techniques that have been used in the treatment of migraines include Cognitive Behavioral Therapy (CBT), relaxation training, biofeedback, Acceptance and commitment therapy (ACT), as well as mindfulness-based therapies. ^[157] A 2024 systematic literature review and meta analysis found evidence that treatments such as CBT, relaxation training, ACT, and mindfulness-based therapies can reduce migraine frequency both on their own and in combination with other treatment options. ^[157] For children and adolescents, CBT and biofeedback strategies are effective in decreasing of frequency and intensity of migraines. These techniques often include relaxation methods and promotion of long-term management without medication side effects, which is emphasized for younger individuals. ^[157]

A variety of possible diets have been proposed, including ketogenic diet, ^{[158] [159]} Mediterranean diet, DASH diet, and high intakes of fruits, vegetables, legumes, and oil seeds. ^[160] Further research is needed to examine whether and when dietary interventions are beneficial. ^[155] Interventions such as transcranial magnetic stimulation and transcutaneous supraorbital nerve stimulation require further research. ^{[161] [162]}

Preventive medications may be recommended for those experiencing frequent or severe migraines. ^[163] Preventive medications include beta blockers, topiramate, and calcitonin gene related peptides (CGRP) inhibitors like erenumab and galcanezumab, which have demonstrated significant efficacy in clinical studies. ^[164] Prokinetic antiemetics are used as adjunctives for patients with nausea and/or vomiting. ^[53] Corticosteroids such as dexamethasone have been used to treat patients with status migrainosus, ^[165] severe baseline disability, or refractory or recurrent headaches. ^{[166] [167]}

Acute treatment

Acute treatments are most effective when administered early in an attack. ^[163] Initial recommended treatment for acute mild to moderate attacks is with over-the-counter (OTC) medications such as ibuprofen (Advil, Motrin) and paracetamol (acetaminophen, Tylenol) for pain. ^[16] Triptans are recommended as a first-line therapy for moderate to severe attacks. ^[16] The approval of CGRP inhibitors (gepants) is seen as a major advance in migraine treatment. ^{[17] [18]} According to the American Headache Society, CGRP targeting therapies are a first-line option for migraine prevention. ^{[168] [169]} Anti-nausea medications are used as a second-line treatment for migraine-related nausea. ^[16] Ergotamines may be used by those experiencing headaches that do not respond to over-the-counter pain medications. ^{[19] [16]} Opioids should not be prescribed, as higher doses of opioids are linked to medication overuse headache (MOH) and increased risk of progression from episodic to chronic migraines. ^{[170] [171]}

Systematic review and network meta analysis comparing the effectiveness of medications for acute migraine attacks in adults suggest that triptans, ditans, and gepants are all associated with reduced pain after 2 hours, with triptans being the most successful in reducing pain. Gepants were the least likely to involve adverse events, with some triptans having a higher risk than gepants, and ditans having the highest risk among all treatments. ^[172]

Prognosis

For those with occasional, episodic migraine, a "proper combination of drugs for prevention and treatment of migraine attacks" can limit the disease's impact on patients' personal and professional lives. ^[173] Fewer than half of people with migraine seek medical care. ^[174] Severe migraine ranks in the highest category of disability, according to the World Health Organization, which uses metrics to determine disability burden, ^[175] and the bulk of disability burden is due to chronic (as opposed to episodic) migraine. ^[176]

Repeated experiences of pain, including migraine pain, cause functional and structural changes in the brain ^[176] It is possible for migraine to progress from an occasional inconvenience to a life-changing, chronic disorder. This "chronification" affects 3% of migraineurs in a given year, such that 8% of migraineurs have chronic migraine in any given year. Brain imagery reveals that the electrophysiological changes seen during an attack become permanent in people with chronic migraine; "thus, from an electrophysiological point of view, chronic migraine indeed resembles a never-ending migraine attack." ^[176]

Factors such as genetic predisposition and hormones complicate the risk profile of those with migraine. There are significant differences between women who do and do not experience aura in terms of symptoms, mechanisms, and treatment. ^{[26] [177]} Migraine with aura is associated with an increased risk of ischemic stroke, myocardial infarction, coronary artery disease, and coronary artery dissection (SCAD). This may reflect shared underlying mechanisms of migraine with aura and cardiovascular disease. ^[177] Women who experience migraine with aura and use estrogen-containing oral contraceptives have a higher risk of ischemic stroke. ^{[26] [177]} In contrast, migraine generally, and migraine without aura, do not appear be related to increased risk of stroke or heart disease. ^[178] Preventative therapy, particularly for those with migraine with aura, may prevent associated strokes. ^[179]

People with migraine, particularly women, may develop higher than average numbers of white matter brain lesions of unclear significance. ^[5]

Epidemiology

Percent of women and men who have experienced migraine with or without aura within the last 3 months

Migraine is common, with around 33% of women and 18% of men affected at some point in their lifetime. ^[30] Onset can be at any age, but prevalence rises sharply around puberty, and remains high until declining after age 50. ^[30] Before puberty, boys and girls are equally impacted, with around 5% of children experiencing migraine attacks. From puberty onwards, women experience migraine attacks at greater rates than men. From age 30 to 50, up to 4 times as many women experience migraine attacks as men; ^[30] this is most pronounced in migraine without aura. ^[88]

According to the Global Burden of Disease 2021 database approximately 14% (1.16 billion) of people worldwide are affected by migraine. ^[23] In the United States, about 6% of men and 18% of women experience a migraine attack in a given year, with a lifetime risk of about 18% and 43%, respectively. ^[32] In Europe, migraine affects 12–28% of people at some point in their lives, with about 6–15% of adult men and 14–35% of adult women getting at least one attack yearly. ^[180] Rates of migraine are slightly lower in Asia and Africa than in Western countries. ^[181] Chronic migraine occurs in approximately 1.4–2.2% of the population. ^[182]

Economic impact

Migraine is a significant source of both medical costs and lost productivity. It has been estimated that migraine is the most costly headache disorder in the European Community, costing € 50–111 billion per year in 2012. Most of the costs were due to lost work. ^[183] As of 2017, in the United States, total costs were estimated at US$ 78 billion, with the cost per person multiple times bigger for those with chronic migraines. ^[184] In those who do attend work during a migraine attack, effectiveness is decreased by around a third. ^[185] Negative effects also frequently occur for a person's family. ^[185]

Research

Compared to the disease burden of migraine, the amount of healthy life years lost, the field is severely underfunded. In the US in 2019, migraine research got just 7.8% of the funding expected based on its burden. In Europe it was the most underfunded brain disease when compared to economic impact. ^[186]

History

The Head Ache, George Cruikshank (1819)

An early description consistent with migraine is contained in the Ebers Papyrus, written around 1500 BCE in ancient Egypt. ^[187]

The word migraine is from the Greek ἡμικρᾱνίᾱ (hēmikrāníā), 'pain in half of the head', ^[188] from ἡμι- (hēmi-), 'half' and κρᾱνίον (krāníon), 'skull'. ^[189]

In 200 BCE, writings from the Hippocratic school of medicine described the visual aura that can precede the headache and a partial relief occurring through vomiting. ^[190]

A second-century description by Aretaeus of Cappadocia divided headaches into three types: cephalalgia, cephalea, and heterocrania. ^[191] Galen of Pergamon used the term hemicrania (half-head), from which the word migraine was eventually derived. ^[191] Galen also proposed that the pain arose from the meninges and blood vessels of the head. ^[190] Migraine was first divided into the two now used types – migraine with aura (migraine ophthalmique) and migraine without aura (migraine vulgaire) in 1887 by Louis Hyacinthe Thomas, a French librarian. ^[190] The mystical visions of Hildegard von Bingen, which she described as "reflections of the living light", are consistent with the visual aura experienced during migraine attacks. ^[192]

A trepanated skull, from the Neolithic. The perimeter of the hole in the skull is rounded off by ingrowth of new bony tissue, indicating that the person survived the operation.

Trepanation, the deliberate drilling of holes into a skull, was practiced as early as 7,000 BCE. ^[187] While sometimes people survived, many would have died from the procedure due to infection. ^[193] It was believed to work via "letting evil spirits escape". ^[194] William Harvey recommended trepanation as a treatment for migraine in the 17th century. ^[195] The association between trepanation and headaches in ancient history may simply be a myth or unfounded speculation that originated several centuries later. In 1913, the world-famous American physician William Osler misinterpreted the French anthropologist and physician Paul Broca's words about a set of children's skulls from the Neolithic age that he found during the 1870s. These skulls presented no evident signs of fractures that could justify this complex surgery for mere medical reasons. Trepanation was probably born of superstitions, to remove "confined demons" inside the head, or to create healing or fortune talismans with the bone fragments removed from the skulls of the patients. However, Osler wanted to make Broca's theory more palatable to his modern audiences, and explained that trepanation procedures were used for mild conditions such as "infantile convulsions headache and various cerebral diseases believed to be caused by confined demons." ^[196]

While many treatments for migraine have been attempted, it was not until 1868 that use of a substance that eventually turned out to be effective began. ^[190] This substance was the fungus ergot from which ergotamine was isolated in 1918 ^[197] and first used to treat migraine in 1925. ^[198] Methysergide was developed in 1959 and the first triptan, sumatriptan, was developed in 1988. ^[197] During the 20th century, with better study design, effective preventive measures were found and confirmed. ^[190]

See also

• List of investigational headache and migraine drugs

Notes

1. Pronounced as US: UK: /ˈmaɪɡreɪn/ , UK also /ˈmiː-/ ^{[1] [2]}

References

1. Wells JC (2008). Longman Pronunciation Dictionary (3rd ed.). Longman. ISBN   978-1-4058-8118-0.
2. Jones D (2011). Roach P, Setter J, Esling J (eds.). Cambridge English Pronouncing Dictionary (18th ed.). Cambridge University Press. ISBN   978-0-521-15255-6.
3. Pescador Ruschel MA, De Jesus O (2024). "Migraine Headache". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   32809622 . Retrieved 13 September 2024.
4. "Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition". Cephalalgia. 38 (1): 1–211. January 2018. doi:10.1177/0333102417738202. PMID   29368949.
5. Fernandes C, Dapkute A, Watson E, Kazaishvili I, Chądzyński P, Varanda S, et al. (19 December 2024). "Migraine and cognitive dysfunction: a narrative review". The Journal of Headache and Pain. 25 (1): 221. doi: 10.1186/s10194-024-01923-y . PMC   11657937 . PMID   39701926.
6. Katsarava Z, Buse DC, Manack AN, Lipton RB (February 2012). "Defining the differences between episodic migraine and chronic migraine". Current Pain and Headache Reports. 16 (1): 86–92. doi:10.1007/s11916-011-0233-z. PMC   3258393 . PMID   22083262.
7. Shankar Kikkeri N, Nagalli S (December 2022). "Migraine With Aura". StatPearls Publishing. PMID   32119498. Bookshelf ID: NBK554611. Archived from the original on 8 June 2023. Retrieved 23 August 2023.
8. Lipton RB, Buse DC, Nahas SJ, Tietjen GE, Martin VT, Löf E, et al. (December 2023). "Risk factors for migraine disease progression: a narrative review for a patient-centered approach". Journal of Neurology. 270 (12): 5692–5710. doi:10.1007/s00415-023-11880-2. PMC   10632231 . PMID   37615752.
9. Burstein R, Noseda R, Borsook D (April 2015). "Migraine: multiple processes, complex pathophysiology". The Journal of Neuroscience. 35 (17): 6619–6629. doi:10.1523/JNEUROSCI.0373-15.2015. PMC   4412887 . PMID   25926442.
10. Ashina S, Bentivegna E, Martelletti P, Eikermann-Haerter K (June 2021). "Structural and Functional Brain Changes in Migraine". Pain and Therapy. 10 (1): 211–223. doi:10.1007/s40122-021-00240-5. PMC   8119592 . PMID   33594593.
11. Levy D, Moskowitz MA (10 July 2023). "Meningeal Mechanisms and the Migraine Connection". Annual Review of Neuroscience. 46: 39–58. doi:10.1146/annurev-neuro-080422-105509. ISSN   0147-006X. PMC   11412714 . PMID   36913712.
12. Haghdoost F, Togha M (January 2022). "Migraine management: Non-pharmacological points for patients and health care professionals". Open Medicine. 17 (1): 1869–1882. doi: 10.1515/med-2022-0598 . PMC   9691984 . PMID   36475060.
13. Altamura C, Coppola G, Vernieri F (1 January 2024). "The evolving concept of multimorbidity and migraine". In Swanson JW, Matharu M (eds.). Handbook of Clinical Neurology, Vol. 199 (3rd series) Migraine Management. Vol. 199. Elsevier. pp. 535–566. doi:10.1016/B978-0-12-823357-3.00014-8. ISBN   978-0-12-823357-3. PMID   38307670.
14. Stubberud A, Buse DC, Kristoffersen ES, Linde M, Tronvik E (20 December 2021). "Is there a causal relationship between stress and migraine? Current evidence and implications for management". The Journal of Headache and Pain. 22 (1): 155. doi: 10.1186/s10194-021-01369-6 . PMC   8685490 . PMID   34930118.
15. Daou M, Vgontzas A (August 2024). "Sleep Symptoms in Migraine". Current Neurology and Neuroscience Reports. 24 (8): 245–254. doi:10.1007/s11910-024-01346-x. PMID   38864968.
16. Wiley AT, Watson JC, Lehmann DN (April 2025). "Acute Migraine Headache: Treatment Strategies". American Family Physician. 111 (4): 317–327. PMID   40238974.
17. Zobdeh F, Ben Kraiem A, Attwood MM, Chubarev VN, Tarasov VV, Schiöth HB, et al. (December 2021). "Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments". British Journal of Pharmacology. 178 (23): 4588–4607. doi:10.1111/bph.15657. PMID   34379793.
18. Younis S, Latysheva NV, Danilov AB, Ashina M (1 January 2024). "CGRP receptor antagonists (gepants)". In Swanson JW, Matharu M (eds.). Handbook of Clinical Neurology, Vol. 199 (3rd series) Migraine Management. Elsevier. pp. 51–66. ISBN   978-0-12-823357-3.
19. Tzankova V, Becker WJ, Chan TL (January 2023). "Diagnosis and acute management of migraine". CMAJ. 195 (4): E153–E158. doi:10.1503/cmaj.211969. PMC   9888545 . PMID   36717129.
20. Duncan CW, Silberstein SD (1 January 2024). "Evidence-based preventive treatment of migraine". In Swanson JW, Matharu M (eds.). Handbook of Clinical Neurology, Vol. 199 (3rd series) Migraine Management. Vol. 199. Elsevier. pp. 219–241. doi:10.1016/B978-0-12-823357-3.00030-6. ISBN   978-0-12-823357-3. PMID   38307648.
21. Aguilar-Shea AL, Membrilla Md JA, Diaz-de-Teran J (February 2022). "Migraine review for general practice". Atencion Primaria. 54 (2) 102208. doi:10.1016/j.aprim.2021.102208. PMC   8605054 . PMID   34798397.
22. Kumar A, Kadian R (September 2022). "Migraine Prophylaxis". StatPearls Publishing. PMID   29939650. Bookshelf ID: NBK507873. Archived from the original on 8 March 2023. Retrieved 22 August 2023.
23. Dong L, Dong W, Jin Y, Jiang Y, Li Z, Yu D (February 2025). "The Global Burden of Migraine: A 30-Year Trend Review and Future Projections by Age, Sex, Country, and Region". Pain and Therapy. 14 (1): 297–315. doi:10.1007/s40122-024-00690-7. PMC   11751287 . PMID   39661241.
24. Lu Y, Li QY, Gan L, You Y, Wang CD, Guo ZW, et al. (2025). "The global and regional burden and trends of migraine from 1990 to 2021: Global Burden of Disease Study 2021". Frontiers in Neurology. 16 1686288. doi: 10.3389/fneur.2025.1686288 . PMC   12620191 . PMID   41255791.
25. Treadwell JR, Tsou AY, Rouse B, Ivlev I, Fricke J, Buse D, et al. (18 September 2024). Behavioral Interventions for Migraine Prevention. Agency for Healthcare Research and Quality (AHRQ). doi:10.23970/AHRQEPCCER270. PMID   39471258.
26. Kuruvilla DE, Hutchinson S, Moriarty M, Abbott C, Brown A, Leroue C, et al. (January 2025). "Understanding migraine throughout a woman's life and the role of calcitonin gene-related peptide: A narrative review". Women's Health (London, England). 21 17455057251376878. doi:10.1177/17455057251376878. PMC   12547133 . PMID   41109841.
27. Denney DE, Hendry M, Pahlevan N, Ayaz A, Denney DA (16 May 2024). "Migraine Throughout a Woman's Life: A Guide to Management". Journal of the Mississippi State Medical Association. 65 (5/6).
28. Allais G, Chiarle G, Sinigaglia S, Airola G, Schiapparelli P, Benedetto C (2020). "Gender-related differences in migraine". Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 41 (Suppl 2): 429–436. doi:10.1007/s10072-020-04643-8. ISSN   1590-3478. PMC   7704513 . PMID   32845494.
29. Bugge NS, Vetvik KG, Alstadhaug KB, Braaten T (20 June 2025). "Migraine through puberty and menopausal transition-data from the population-based Norwegian Women and Health study (NOWAC)". The Journal of Headache and Pain. 26 (1): 145. doi: 10.1186/s10194-025-02083-3 . PMC   12180204 . PMID   40542382.
30. Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A, et al. (January 2022). "Migraine". Nature Reviews. Disease Primers. 8 (1) 2. doi:10.1038/s41572-021-00328-4. PMID   35027572. S2CID   245883895.
31. Gao L, Zhao F, Tu Y, Liu K (2024). "The prodrome of migraine: mechanistic insights and emerging therapeutic strategies". Frontiers in Neurology. 15 1496401. doi: 10.3389/fneur.2024.1496401 . PMC   11638031 . PMID   39677861.
32. Bartleson JD, Cutrer FM (May 2010). "Migraine update. Diagnosis and treatment". Minnesota Medicine. 93 (5): 36–41. PMID   20572569.
33. Headache Classification Subcommittee of the International Headache Society (2013). "The International Classification of Headache Disorders: 3rd edition". Cephalalgia. 33 (9): 644–648. doi: 10.1177/0333102413485658 . PMID   23771276.
34. Dodick DW (May 2018). "A Phase-by-Phase Review of Migraine Pathophysiology". Headache. 58 Suppl 1: 4–16. doi:10.1111/head.13300. PMID   29697154.
35. Hougaard A, Ayata C, Brennan KC, van den Maagdenberg A, Ashina M (June 2025). "The mysterious link between migraine aura and migraine headache". PLOS Biology. 23 (6) e3003168. doi: 10.1371/journal.pbio.3003168 . PMC   12157119 . PMID   40498799.
36. Raggi A, Leonardi M, Arruda M, Caponnetto V, Castaldo M, Coppola G, et al. (31 October 2024). "Hallmarks of primary headache: part 1 - migraine". The Journal of Headache and Pain. 25 (1): 189. doi: 10.1186/s10194-024-01889-x . PMC   11529271 . PMID   39482575.
37. Allais G, Chiarle G, Sinigaglia S, Airola G, Schiapparelli P, Benedetto C (December 2020). "Gender-related differences in migraine". Neurological Sciences. 41 (Suppl 2): 429–436. doi:10.1007/s10072-020-04643-8. PMC   7704513 . PMID   32845494.
38. Kamourieh S, Rozen T, Anderson JM (2024). "Status migrainosus". Migraine Management. Handbook of Clinical Neurology. Vol. 199. pp. 413–439. doi:10.1016/B978-0-12-823357-3.00017-3. ISBN   978-0-12-823357-3. PMID   38307660.
39. Arca KN, Halker Singh RB (15 July 2021). "Dehydration and Headache". Current Pain and Headache Reports. 25 (8): 56. doi:10.1007/s11916-021-00966-z. PMC   8280611 . PMID   34268642.
40. Orr SL (17 January 2023). "Status Migrainosus: One of the Most Poorly Understood but Important Complications of Migraine". Neurology. 100 (3): 107–108. doi:10.1212/WNL.0000000000201477. PMID   36175154.
41. Sousa-Santos P, Peres M (July 2025). "Practical issues in the management of sleep, anxiety, and mood disorders in primary headaches". Arquivos de Neuro-psiquiatria. 83 (7): 001–008. doi:10.1055/s-0045-1809881. PMC   12221693 . PMID   40602800.
42. Grodzka O, Dzagoevi K, Rees T, Cabral G, Chądzyński P, Di Antonio S, et al. (14 April 2025). "Migraine with and without aura-two distinct entities? A narrative review". The Journal of Headache and Pain. 26 (1): 77. doi: 10.1186/s10194-025-01998-1 . PMC   11995571 . PMID   40229683.
43. Eigenbrodt AK, Christensen RH, Ashina H, Iljazi A, Christensen CE, Steiner TJ, et al. (12 November 2022). "Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency". The Journal of Headache and Pain. 23 (1): 140. doi: 10.1186/s10194-022-01510-z . PMC   9655795 . PMID   36371152.
44. Sebastianelli G, Atalar AÇ, Cetta I, Farham F, Fitzek M, Karatas-Kursun H, et al. (October 2024). "Insights from triggers and prodromal symptoms on how migraine attacks start: The threshold hypothesis". Cephalalgia. 44 (10) 3331024241287224. doi:10.1177/03331024241287224. PMID   39380339.
45. "MIGRAINE PRODROME: SYMPTOMS AND PREVENTION". American Migraine Foundation. 17 March 2022.
46. Ashina M (November 2020). "Migraine". The New England Journal of Medicine. 383 (19): 1866–1876. doi:10.1056/NEJMra1915327. PMID   33211930. S2CID   227078662.
47. Severino M, Green MW (1 June 2025). "Persistent aura without infarction". Current Opinion in Neurology. 38 (3): 249–253. doi:10.1097/WCO.0000000000001357. PMID   40062461.
48. Tukur HN, Uwishema O, Sheikhah D, Akbay H (11 August 2025). "Neuro-ophthalmology and migraine: visual aura and its neural basis". International Journal of Emergency Medicine. 18 (1): 148. doi: 10.1186/s12245-025-00924-1 . PMC   12337509 . PMID   40790166.
49. Weatherall MW (5 November 2021). "From "Transient Hemiopsia" to Migraine Aura". Vision (Basel). 5 (4): 54. doi: 10.3390/vision5040054 . PMC   8628937 . PMID   34842837.
50. Nordin BA (August 2025). "Differentiating Visual Symptoms in Retinal Migraine and Migraine With Aura: A Systematic Review of Shared Features, Distinctions, and Clinical Implications". Cureus. 17 (8) e91028. doi: 10.7759/cureus.91028 . PMC   12380025 . PMID   40873917.
51. Joppeková Ľ, Pinto MJ, da Costa MD, Boček R, Berman G, Salim Y, et al. (1 July 2025). "What does a migraine aura look like?-A systematic review". The Journal of Headache and Pain. 26 (1): 149. doi: 10.1186/s10194-025-02080-6 . PMC   12210593 . PMID   40597581.
52. Qubty W, Patniyot I (June 2020). "Migraine Pathophysiology". Pediatric Neurology. 107: 1–6. doi:10.1016/j.pediatrneurol.2019.12.014. PMID   32192818. S2CID   213191464.
53. Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, et al. (August 2021). "Diagnosis and management of migraine in ten steps". Nature Reviews. Neurology. 17 (8): 501–514. doi:10.1038/s41582-021-00509-5. PMC   8321897 . PMID   34145431.
54. Khan A, Liu S, Tao F (6 March 2025). "Current Trends in Pediatric Migraine: Clinical Insights and Therapeutic Strategies". Brain Sciences. 15 (3): 280. doi: 10.3390/brainsci15030280 . PMC   11940401 . PMID   40149800.
55. Villar-Martinez MD, Goadsby PJ (September 2022). "Pathophysiology and Therapy of Associated Features of Migraine". Cells. 11 (17): 2767. doi: 10.3390/cells11172767 . PMC   9455236 . PMID   36078174.
56. Al Kadri L, Alhouri AN, Nahas LD (21 February 2025). "Assessing the relationship between migraine and sino-nasal symptoms and diseases among Syrian Private University students: A case-control study". Medicine. 104 (8) e41680. doi:10.1097/MD.0000000000041680. PMC   11856896 . PMID   39993086.
57. Gorenshtein A, Shihada K, Leibovitch L, Liba T, Goren A (August 2025). "The association between migraine and gut microbiota: a systematic review". Acta Neurologica Belgica. 125 (4): 977–987. doi:10.1007/s13760-025-02779-y. PMC   12391207 . PMID   40175732.
58. Rees TA, Doukhi D, Wang VS, Balcerbula A, Bravo M, Fathi H, et al. (October 2025). "Neck pain in migraine: A narrative review and steps to correct evaluation and treatment". Cephalalgia. 45 (10) 3331024251387449. doi: 10.1177/03331024251387449 . PMID   41134815.
59. Hensel O, Kraya T (January 2025). "Primary Headache Attributed to External Compression or Traction to the Head: A Narrative Review". Brain and Behavior. 15 (1) e70202. doi:10.1002/brb3.70202. PMC   11685174 . PMID   39740198.
60. Kaniecki R (2024). "Migraine with brainstem aura". Migraine Management. Handbook of Clinical Neurology. Vol. 199. pp. 367–379. doi:10.1016/B978-0-12-823357-3.00019-7. ISBN   978-0-12-823357-3. PMID   38307657.
61. Van Der Donckt J, Vandenbussche N, De Brouwer M, Steenwinckel B, Stojchevska M, Ongenae F, et al. (13 February 2025). "Analysis of free-living daytime movement in patients with migraine with access to acute treatment". The Journal of Headache and Pain. 26 (1): 33. doi: 10.1186/s10194-025-01971-y . PMC   11823234 . PMID   39948510.
62. Woldeamanuel YW (19 June 2025). "Exercise Patterns and Migraine Management: A Multifaceted Approach". American Journal of Lifestyle Medicine 15598276251346394. doi:10.1177/15598276251346394. PMC   12181186 . PMID   40547534.
63. Amin FM, Aristeidou S, Baraldi C, Czapinska-Ciepiela EK, Ariadni DD, Di Lenola D, et al. (September 2018). "The association between migraine and physical exercise". The Journal of Headache and Pain. 19 (1) 83. doi: 10.1186/s10194-018-0902-y . PMC   6134860 . PMID   30203180.
64. Do TP, Hougaard A, Dussor G, Brennan KC, Amin FM (10 January 2023). "Migraine attacks are of peripheral origin: the debate goes on". The Journal of Headache and Pain. 24 (1): 3. doi: 10.1186/s10194-022-01538-1 . PMC   9830833 . PMID   36627561.
65. Robblee J (21 August 2019). "Silent Migraine: A Guide". American Migraine Foundation. Archived from the original on 28 January 2021. Retrieved 22 January 2021.
66. He Y, Li Y, Nie Z (February 2015). "Typical aura without headache: a case report and review of the literature". Journal of Medical Case Reports. 9 (1) 40. doi: 10.1186/s13256-014-0510-7 . PMC   4344793 . PMID   25884682.
67. Thuraiaiyah J, Ashina H, Christensen RH, Al-Khazali HM, Ashina M (21 February 2024). "Postdromal symptoms in migraine: a REFORM study". The Journal of Headache and Pain. 25 (1): 25. doi: 10.1186/s10194-024-01716-3 . PMC   10880332 . PMID   38383318.
68. Bron C, Sutherland HG, Griffiths LR (2021). "Exploring the Hereditary Nature of Migraine". Neuropsychiatric Disease and Treatment. 17: 1183–1194. doi: 10.2147/NDT.S282562 . PMC   8075356 . PMID   33911866.
69. Duan S, Ren Z, Xia H, Wang Z, Zheng T, Li G, et al. (2023). "Associations between anxiety, depression with migraine, and migraine-related burdens". Frontiers in Neurology. 14 1090878. doi: 10.3389/fneur.2023.1090878 . PMC   10166814 . PMID   37181566.
70. Grangeon L, Lange KS, Waliszewska-Prosół M, Onan D, Marschollek K, Wiels W, et al. (20 February 2023). "Genetics of migraine: where are we now?". The Journal of Headache and Pain. 24 (1): 12. doi: 10.1186/s10194-023-01547-8 . PMC   9940421 . PMID   36800925.
71. Olofsson IA (September 2024). "Migraine heritability and beyond: A scoping review of twin studies". Headache. 64 (8): 1049–1058. doi:10.1111/head.14789. PMID   39023388.
72. Gormley P, Kurki MI, Hiekkala ME, Veerapen K, Häppölä P, Mitchell AA, et al. (May 2018). "Common Variant Burden Contributes to the Familial Aggregation of Migraine in 1,589 Families". Neuron. 98 (4): 743–753.e4. doi:10.1016/j.neuron.2018.04.014. PMC   5967411 . PMID   29731251.
73. Harder AV, Terwindt GM, Nyholt DR, van den Maagdenberg AM (February 2023). "Migraine genetics: Status and road forward". Cephalalgia. 43 (2) 3331024221145962. doi: 10.1177/03331024221145962 . PMID   36759319.
74. Wang YF (1 April 2025). "Is migraine a common manifestation of CADASIL-Cons". The Journal of Headache and Pain. 26 (1) 65. doi: 10.1186/s10194-025-01981-w . PMC   11963438 . PMID   40170160.
75. Cabañero D, Carter EP, González-Cano R, Cobos EJ, Fernández-Carvajal A, Ferrer-Montiel A (23 June 2025). "Cold receptor TRPM8 as a target for migraine-associated pain and affective comorbidities". The Journal of Headache and Pain. 26 (1): 146. doi: 10.1186/s10194-025-02082-4 . PMC   12183901 . PMID   40545528.
76. Wei C, Kim B, McKemy DD (1 December 2022). "Transient receptor potential melastatin 8 is required for nitroglycerin- and calcitonin gene-related peptide-induced migraine-like pain behaviors in mice". Pain. 163 (12): 2380–2389. doi:10.1097/j.pain.0000000000002635. PMC   9519811 . PMID   35353773.
77. Wan D, Wang C, Zhang X, Tang W, Chen M, Dong Z, et al. (January 2016). "Association between angiotensin-converting enzyme insertion/deletion polymorphism and migraine: a meta-analysis". The International Journal of Neuroscience. 126 (5): 393–9. doi:10.3109/00207454.2015.1025395. PMID   26000817. S2CID   34902092.
78. Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, Wilt TJ, Harrod CS, Tice JA, et al. (March 2025). "Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians". Annals of Internal Medicine. 178 (3): 426–433. doi:10.7326/ANNALS-24-01052. PMID   39899861.
79. Bjornsdottir G, Chalmer MA, Stefansdottir L, Skuladottir AT, Einarsson G, Andresdottir M, et al. (November 2023). "Rare variants with large effects provide functional insights into the pathology of migraine subtypes, with and without aura". Nature Genetics. 55 (11): 1843–1853. doi:10.1038/s41588-023-01538-0. PMC   10632135 . PMID   37884687.
80. Hautakangas H, Winsvold BS, Ruotsalainen SE, Bjornsdottir G, Harder AV, Kogelman LJ, et al. (February 2022). "Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles". Nature Genetics. 54 (2): 152–160. doi:10.1038/s41588-021-00990-0. PMC   8837554 . PMID   35115687.
81. Mikol DD, Picard H, Klatt J, Wang A, Peng C, Stefansson K (April 2020). "Migraine Polygenic Risk Score Is Associated with Severity of Migraine – Analysis of Genotypic Data from Four Placebo-controlled Trials of Erenumab (1214)". Neurology. 94 (15_supplement) 1214. doi:10.1212/WNL.94.15_supplement.1214.
82. Kogelman LJ, Esserlind AL, Francke Christensen A, Awasthi S, Ripke S, Ingason A, et al. (December 2019). "Migraine polygenic risk score associates with efficacy of migraine-specific drugs". Neurology. Genetics. 5 (6) e364. doi:10.1212/NXG.0000000000000364. PMC   6878840 . PMID   31872049.
83. Kesserwani H (1 April 2021). "Migraine Triggers: An Overview of the Pharmacology, Biochemistry, Atmospherics, and Their Effects on Neural Networks". Cureus. 13 (4) e14243. doi: 10.7759/cureus.14243 . PMC   8088284 . PMID   33954064.
84. Karsan N, Bose P, Newman J, Goadsby PJ (May 2021). "Are some patient-perceived migraine triggers simply early manifestations of the attack?". Journal of Neurology. 268 (5): 1885–1893. doi:10.1007/s00415-020-10344-1. PMC   8068686 . PMID   33399964.
85. "Migraine Triggers: Avoid or Cope?". Migraine Canada. 28 June 2024. Retrieved 11 November 2025.
86. Smith L (6 February 2025). "Osmophobia and Migraine". Association of Migraine Disorders. Retrieved 17 November 2025.
87. Jenkins, B. Migraine management. Australian Prescriber. 2020; 43(5):148–151. https://doi.org/10.18773/austprescr.2020.047
88. Chalmer MA, Kogelman LJ, Callesen I, Christensen CG, Techlo TR, Møller PL, et al. (June 2023). "Sex differences in clinical characteristics of migraine and its burden: a population-based study". European Journal of Neurology. 30 (6): 1774–1784. doi:10.1111/ene.15778. PMID   36905094.
89. Pavlović JM (2020). "The impact of midlife on migraine in women: summary of current views". Women's Midlife Health. 6 11. doi: 10.1186/s40695-020-00059-8 . PMC   7542111 . PMID   33042563.
90. Reddy N, Desai MN, Schoenbrunner A, Schneeberger S, Janis JE (10 March 2021). "The complex relationship between estrogen and migraines: a scoping review". Systematic Reviews. 10 (1): 72. doi: 10.1186/s13643-021-01618-4 . PMC   7948327 . PMID   33691790.
91. Penzien DB, Irby MB (1 January 2024). "Biobehavioral treatments of migraine". In Swanson JW, Matharu M (eds.). Handbook of Clinical Neurology, Vol. 199 (3rd series) Migraine Management. Vol. 199. Elsevier. pp. 155–169. doi:10.1016/B978-0-12-823357-3.00031-8. ISBN   978-0-12-823357-3. PMID   38307643.
92. Sturgeon JA, Ehde DM, Darnall BD, Barad MJ, Clauw DJ, Jensen MP (June 2023). "Psychological Approaches for Migraine Management". Anesthesiology Clinics. 41 (2): 341–355. doi:10.1016/j.anclin.2023.02.002. PMC   10513739 . PMID   37245946.
93. Elmazny A, Magdy R, Hussein M, Ismaeel AY, Essmat A, Elbeltagy KE, et al. (1 September 2025). "Migraine triggers and lifestyle modifications: an assessment of patients' awareness and the role of healthcare providers in patient education". The Journal of Headache and Pain. 26 (1): 189. doi: 10.1186/s10194-025-02107-y . PMC   12400567 . PMID   40890611.
94. Woldeamanuel YW, Rahman A, Hyimanot ET, Chirravuri R, Fani M, Javaheri ED, et al. (2025). "Disrupting the clock: Meta-analysis of irregular night shifts and migraine, proposing shift work migraine disorder with chronobiology strategies". Frontiers in Neurology. 16 1684169. doi: 10.3389/fneur.2025.1684169 . medRxiv   10.1101/2025.07.31.25332540 . PMC   12728237 . PMID   41451422.
95. Stanyer EC, Brookes J, Pang JR, Urani A, Holland PR, Hoffmann J (8 September 2023). "Investigating the relationship between sleep and migraine in a global sample: a Bayesian cross-sectional approach". The Journal of Headache and Pain. 24 (1): 123. doi: 10.1186/s10194-023-01638-6 . PMC   10486047 . PMID   37679693.
96. Leso V, Gervetti P, Mauro S, Macrini MC, Ercolano ML, Iavicoli I (January 2020). "Shift work and migraine: A systematic review". Journal of Occupational Health. 62 (1) e12116. doi:10.1002/1348-9585.12116. PMC   7154593 . PMID   32515906.
97. Göbel CH, Heinze-Kuhn K, Heinze A, Cirkel A, Göbel H (5 March 2025). "The Impact of Biseasonal Time Changes on Migraine". Neurology International. 17 (3): 40. doi: 10.3390/neurolint17030040 . PMC   11944957 . PMID   40137461.
98. Liu J, Wu T, Liu Q, Wu S, Chen JC (July 2020). "Air pollution exposure and adverse sleep health across the life course: A systematic review". Environmental Pollution. 262 114263. Bibcode:2020EPoll.26214263L. doi:10.1016/j.envpol.2020.114263. PMC   7877449 . PMID   32443219.
99. Yan J, Wang X, Ding B, Zhang M, He Q, Zeng Y, et al. (2025). "Household fuel use and migraine among Chinese adults aged 45 years and older: The modifying effects of sleep". PLOS ONE. 20 (12) e0335407. Bibcode:2025PLoSO..2035407Y. doi: 10.1371/journal.pone.0335407 . PMC   12668480 . PMID   41325283.
100. Robblee J, Starling AJ (November 2019). "SEEDS for success: Lifestyle management in migraine". Cleveland Clinic Journal of Medicine. 86 (11): 741–749. doi: 10.3949/ccjm.86a.19009 . PMID   31710587.
101. Waliszewska-Prosół M, Nowakowska-Kotas M, Chojdak-Łukasiewicz J, Budrewicz S (24 May 2021). "Migraine and Sleep-An Unexplained Association?". International Journal of Molecular Sciences. 22 (11): 5539. doi: 10.3390/ijms22115539 . PMC   8197397 . PMID   34073933.
102. Duan S, Ren Z, Xia H, Wang Z, Zheng T, Liu Z (2022). "Association between sleep quality, migraine and migraine burden". Frontiers in Neurology. 13 955298. doi: 10.3389/fneur.2022.955298 . PMC   9459411 . PMID   36090858.
103. Legesse SM, Addila AE, Jena BH, Jikamo B, Abdissa ZD, Hailemarim T (26 March 2025). "Irregular meal and migraine headache: a scoping review". BMC Nutrition. 11 (1): 60. doi: 10.1186/s40795-025-01048-8 . PMC   11938733 . PMID   40140884.
104. Özturan A, Şanlıer N, Coşkun Ö (2016). "The Relationship Between Migraine and Nutrition". Turk J Neurol. 22 (2): 44–50. doi: 10.4274/tnd.37132 .
105. Fayed AI, Emam H, Abdel-Fattah AN, Shamloul RM, Elkholy TA, Yassen EM, et al. (20 February 2024). "The correlation between the frequent intake of dietary migraine triggers and increased clinical features of migraine (analytical cross-sectional study from Egypt)". Scientific Reports. 14 (1): 4150. Bibcode:2024NatSR..14.4150F. doi:10.1038/s41598-024-54339-8. PMC   10879089 . PMID   38378909.
106. Deus VL, Bispo E, Franca AS, Gloria M (1 December 2020). "Influence of cocoa clones on the quality and functional properties of chocolate – Nitrogenous compounds". LWT. 134 110202. doi:10.1016/j.lwt.2020.110202. hdl: 1843/41303 . ISSN   0023-6438.
107. Ahdoot E, Cohen F (March 2024). "Unraveling the MSG-Headache Controversy: an Updated Literature Review". Current Pain and Headache Reports. 28 (3): 119–124. doi:10.1007/s11916-023-01198-z. PMID   38079074.
108. Lisicki M, Schoenen J (2021). "Old Habits Die Hard: Dietary Habits of Migraine Patients Challenge our Understanding of Dietary Triggers". Frontiers in Neurology. 12 748419. doi: 10.3389/fneur.2021.748419 . PMC   8636453 . PMID   34867734.
109. Russo A, Coppola G, Pierelli F, Parisi V, Silvestro M, Tessitore A, et al. (2018). "Pain Perception and Migraine". Frontiers in Neurology. 9 576. doi: 10.3389/fneur.2018.00576 . PMC   6082953 . PMID   30116215.
110. Imai N, Osanai A, Moriya A, Katsuki M, Kitamura E (25 May 2023). "Classification of odors associated with migraine attacks: a cross-sectional study". Scientific Reports. 13 (1): 8469. Bibcode:2023NatSR..13.8469I. doi:10.1038/s41598-023-35211-7. PMC   10213061 . PMID   37230996.
111. Wilkins AJ, Haigh SM, Mahroo OA, Plant GT (October 2021). "Photophobia in migraine: A symptom cluster?". Cephalalgia. 41 (11–12): 1240–1248. doi:10.1177/03331024211014633. PMC   8497413 . PMID   33990148.
112. Salvati V, Otani S, Tartaglia EM (2025). "Neural signatures of extreme sensitivities to light: cortical markers in hypersensitive and hyposensitive individuals via EEG". Frontiers in Neuroscience. 19 1542154. doi: 10.3389/fnins.2025.1542154 . PMC   11931066 . PMID   40129722.
113. Fong CY, Law W, Fahrenfort JJ, Braithwaite JJ, Mazaheri A (5 April 2022). "Attenuated alpha oscillation and hyperresponsiveness reveals impaired perceptual learning in migraineurs". The Journal of Headache and Pain. 23 (1): 44. doi: 10.1186/s10194-022-01410-2 . PMC   8981672 . PMID   35382735.
114. Martin LF, Patwardhan AM, Jain SV, Salloum MM, Freeman J, Khanna R, et al. (February 2021). "Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial". Cephalalgia. 41 (2): 135–147. doi:10.1177/0333102420956711. PMC   8034831 . PMID   32903062.
115. Kalita J, Misra UK, Bansal R (March 2021). "Phonophobia and brainstem excitability in migraine". The European Journal of Neuroscience. 53 (6): 1988–1997. doi:10.1111/ejn.15078. PMID   33305448.
116. Mourgela A, Vikelis M, Reiss JD (1 September 2023). "Investigation of Frequency-Specific Loudness Discomfort Levels in Listeners With Migraine: A Case-Control Study". Ear and Hearing. 44 (5): 1007–1013. doi:10.1097/AUD.0000000000001339. PMC   10426780 . PMID   36790444.
117. Kalita J, Bansal R, Mahajan R, Jha V (November 2025). "Effect of High-Rate Repetitive Transcranial Magnetic Stimulation on Phonophobia and Brainstem Auditory Evoked Potential in Migraine". Molecular Neurobiology. 62 (11): 14079–14088. doi:10.1007/s12035-025-05190-z. PMID   40660010.
118. Fornazieri MA, Neto AR, de Rezende Pinna F, Gobbi Porto FH, de Lima Navarro P, Voegels RL, et al. (November 2016). "Olfactory symptoms reported by migraineurs with and without auras". Headache. 56 (10): 1608–1616. doi:10.1111/head.12973. PMID   27779326.
119. Delussi M, Laporta A, Fraccalvieri I, de Tommaso M (18 September 2021). "Osmophobia in primary headache patients: associated symptoms and response to preventive treatments". The Journal of Headache and Pain. 22 (1): 109. doi: 10.1186/s10194-021-01327-2 . PMC   8449918 . PMID   34537019.
120. Gossrau G, Frost M, Klimova A, Koch T, Sabatowski R, Mignot C, et al. (15 July 2022). "Interictal osmophobia is associated with longer migraine disease duration". The Journal of Headache and Pain. 23 (1): 81. doi: 10.1186/s10194-022-01451-7 . PMC   9284850 . PMID   35840888.
121. Meşe Pekdemir E, Tanik N (October 2023). "Clinical significance of osmophobia and its effect on quality of life in people with migraine". Acta Neurologica Belgica. 123 (5): 1747–1755. doi:10.1007/s13760-022-02030-y. PMID   35864435.
122. Kazemi Z, Aboutaleb E, Shahsavani A, Kermani M, Kazemi Z (June 2022). "Evaluation of pollutants in perfumes, colognes and health effects on the consumer: a systematic review". Journal of Environmental Health Science & Engineering. 20 (1): 589–598. Bibcode:2022JEHSE..20..589K. doi:10.1007/s40201-021-00783-x. PMC   9163252 . PMID   35669814.
123. Rádis-Baptista G (1 March 2023). "Do Synthetic Fragrances in Personal Care and Household Products Impact Indoor Air Quality and Pose Health Risks?". Journal of Xenobiotics. 13 (1): 121–131. doi: 10.3390/jox13010010 . PMC   10051690 . PMID   36976159.
124. Li S, Liu Q, Ma M, Fang J, He L (17 April 2025). "Association between weather conditions and migraine: a systematic review and meta-analysis". Journal of Neurology. 272 (5): 346. doi:10.1007/s00415-025-13078-0. PMID   40246758.
125. Denney DE, Lee J, Joshi S (April 2024). "Whether Weather Matters with Migraine". Current Pain and Headache Reports. 28 (4): 181–187. doi:10.1007/s11916-024-01216-8. PMC   10940451 . PMID   38358443.
126. Cioffi I, Farella M, Chiodini P, Ammendola L, Capuozzo R, Klain C, et al. (May 2017). "Effect of weather on temporal pain patterns in patients with temporomandibular disorders and migraine". Journal of Oral Rehabilitation. 44 (5): 333–339. doi:10.1111/joor.12498. PMID   28244179.
127. Biscetti L, Cresta E, Cupini LM, Calabresi P, Sarchielli P (1 May 2023). "The putative role of neuroinflammation in the complex pathophysiology of migraine: From bench to bedside". Neurobiology of Disease. 180 106072. doi: 10.1016/j.nbd.2023.106072 . ISSN   0969-9961. PMID   36907522.
128. Terrier LM, Hadjikhani N, Velut S, Magnain C, Amelot A, Bernard F, et al. (July 2021). "The trigeminal system: The meningovascular complex- A review". Journal of Anatomy. 239 (1): 1–11. doi:10.1111/joa.13413. PMC   8197948 . PMID   33604906.
129. Edvinsson J, Viganò A, Alekseeva A, Alieva E, Arruda R, De Luca C, et al. (5 June 2020). "The fifth cranial nerve in headaches". The Journal of Headache and Pain. 21 (1): 65. doi: 10.1186/s10194-020-01134-1 . PMC   7275328 . PMID   32503421.
130. Arca KN, Lambru G, Starling AJ (1 January 2024). "Neuromodulation in migraine". In Swanson JW, Matharu M (eds.). Handbook of Clinical Neurology, Vol. 199 (3rd series) Migraine Management. Elsevier. pp. 179–200. ISBN   978-0-12-823357-3.
131. Ning J, Zhang Y, Wang Y, Liu C, Cheng Y, Zhu M, et al. (2023). "Exploring the cortical habituation in migraine patients based on contingent negative variation". Frontiers in Neurology. 14 1226554. doi: 10.3389/fneur.2023.1226554 . PMC   10502328 . PMID   37719755.
132. Stankewitz A, Keidel L, Rehm M, Irving S, Kaczmarz S, Preibisch C, et al. (2021). "Migraine attacks as a result of hypothalamic loss of control". NeuroImage. Clinical. 32 102784. doi:10.1016/j.nicl.2021.102784. PMC   8379646 . PMID   34425551.
133. Price S, Daly DT (2025). Neuroanatomy, Trigeminal Nucleus. StatPearls Publishing. PMID   30969645.
134. Betsholtz C, Engelhardt B, Koh GY, McDonald DM, Proulx ST, Siegenthaler J (November 2024). "Advances and controversies in meningeal biology". Nature Neuroscience. 27 (11): 2056–2072. doi:10.1038/s41593-024-01701-8. PMC   11862877 . PMID   39333784.
135. Ogasawara H, Noguchi M (27 October 2021). "Therapeutic Potential of MRGPRX2 Inhibitors on Mast Cells". Cells. 10 (11). doi: 10.3390/cells10112906 . PMID   34831128.
136. Hill A, Amendolara AB, Small C, Guzman SC, Pfister D, McFarland K, et al. (16 October 2024). "Metabolic Pathophysiology of Cortical Spreading Depression: A Review". Brain Sciences. 14 (10): 1026. doi: 10.3390/brainsci14101026 . PMC   11505892 . PMID   39452037.
137. Spekker E, Nagy-Grócz G, Vécsei L (21 November 2023). "Ion Channel Disturbances in Migraine Headache: Exploring the Potential Role of the Kynurenine System in the Context of the Trigeminovascular System". International Journal of Molecular Sciences. 24 (23) 16574. doi: 10.3390/ijms242316574 . PMC   10706278 . PMID   38068897.
138. Mungoven TJ, Henderson LA, Meylakh N (2021). "Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives". Frontiers in Pain Research. 2 705276. doi: 10.3389/fpain.2021.705276 . PMC   8915760 . PMID   35295486.
139. Walling A (1 April 2020). "Frequent Headaches: Evaluation and Management". American Family Physician. 101 (7): 419–428. PMID   32227826.
140. Lipton RB, Buse DC, Nahas SJ, Tietjen GE, Martin VT, Löf E, et al. (December 2023). "Risk factors for migraine disease progression: a narrative review for a patient-centered approach". Journal of Neurology. 270 (12): 5692–5710. doi:10.1007/s00415-023-11880-2. PMC   10632231 . PMID   37615752.
141. Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia, 38(1), 1–211. doi:10.1177/0333102417738202.
142. Evans RW, Burch RC, Frishberg BM, Marmura MJ, Mechtler LL, Silberstein SD, et al. (February 2020). "Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence-Based Guideline". Headache. 60 (2): 318–336. doi:10.1111/head.13720. PMID   31891197.
143. Evans, R. W., Burch, R. C., & Frishberg, B. M. (2020). Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence-Based Guideline. Headache, 60(2), 318–336. doi:10.1111/head.13720.
144. Cousins G, Hijazze S, Van de Laar FA, Fahey T (July–August 2011). "Diagnostic accuracy of the ID Migraine: a systematic review and meta-analysis". Headache. 51 (7): 1140–8. doi:10.1111/j.1526-4610.2011.01916.x. PMID   21649653. S2CID   205684294.
145. Gilmore B, Michael M (February 2011). "Treatment of acute migraine headache". American Family Physician. 83 (3): 271–280. PMID   21302868.
146. Mangrum R, Bryant AL, Gerstein MT, McCarrier KP, Houts CR, McGinley JS, et al. (February 2024). "The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine". Headache. 64 (2): 156–171. doi:10.1111/head.14664. PMC   10922598 . PMID   38235605.
147. "Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition". Cephalalgia. 38 (1): 1–211. January 2018. doi: 10.1177/0333102417738202 . PMID   29368949.
148. Headaches in over 12s: diagnosis and management NICE Clinical Guidelines, No. 150. National Institute for Health and Care Excellence: Clinical Guidelines. London: National Institute for Health and Care Excellence (NICE). 2025. ISBN   978-1-4731-7046-9. PMID   32017486.
149. "Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition". Cephalalgia. 38 (1): 1–211. January 2018. doi:10.1177/0333102417738202. ISSN   0333-1024. PMID   29368949.
150. Negro A, Rocchietti-March M, Fiorillo M, Martelletti P (December 2011). "Chronic migraine: current concepts and ongoing treatments". European Review for Medical and Pharmacological Sciences. 15 (12): 1401–20. PMID   22288302.
151. Azmy DJ, Qualia CM (December 2020). "Review of Abdominal Migraine in Children". Gastroenterology & Hepatology. 16 (12): 632–639. PMC   8132691 . PMID   34035698.
152. Chawla J, Lutsep HL (13 June 2023). "Migraine Headache Treatment & Management". Medscape . Retrieved 3 May 2024.
153. Minen M, George A, Lebowitz N, Katara A, Snyder I (2023). "Headache providers' perspectives of headache diaries in the era of increasing technology use: a qualitative study". Frontiers in Neurology. 14 1270555. doi: 10.3389/fneur.2023.1270555 . PMC   10844531 . PMID   38322798.
154. Buse DC, Reed ML, Fanning KM, Bostic R, Dodick DW, Schwedt TJ, et al. (2 March 2020). "Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study". The Journal of Headache and Pain. 21 (1): 23. doi: 10.1186/s10194-020-1084-y . PMC   7053108 . PMID   32122324.
155. Gazerani P (3 June 2020). "Migraine and Diet". Nutrients. 12 (6): 1658. doi: 10.3390/nu12061658 . PMC   7352457 . PMID   32503158.
156. Barber M, Pace A (11 June 2020). "Exercise and Migraine Prevention: a Review of the Literature". Current Pain and Headache Reports. 24 (8): 39. doi:10.1007/s11916-020-00868-6. PMID   32529311.
157. Treadwell JR, Tsou AY, Rouse B, Ivlev I, Fricke J, Buse D, et al. (2024). Behavioral Interventions for Migraine Prevention (Report). Agency for Healthcare Research and Quality (AHRQ). doi:10.23970/ahrqepccer270. PMID   39471258.
158. Barbanti P, Fofi L, Aurilia C, Egeo G, Caprio M (May 2017). "Ketogenic diet in migraine: rationale, findings and perspectives". Neurological Sciences (Review). 38 (Suppl 1): 111–115. doi:10.1007/s10072-017-2889-6. PMID   28527061. S2CID   3805337.
159. Gross EC, Klement RJ, Schoenen J, D'Agostino DP, Fischer D (April 2019). "Potential Protective Mechanisms of Ketone Bodies in Migraine Prevention". Nutrients. 11 (4): 811. doi: 10.3390/nu11040811 . PMC   6520671 . PMID   30974836.
160. Bakırhan H, Yıldıran H, Uyar Cankay T (November 2022). "Associations between diet quality, DASH and Mediterranean dietary patterns and migraine characteristics". Nutritional Neuroscience. 25 (11): 2324–2334. doi:10.1080/1028415x.2021.1963065. PMID   34379573.
161. Shen M, Li C, Wei X, Zhang L, Li Y, Wu H, et al. (2023). "Transcranial Magnetic Stimulation as a Therapy for Migraine: An Overview of Systematic Reviews". Journal of Pain Research. 16: 3133–3144. doi: 10.2147/JPR.S416993 . PMC   10505396 . PMID   37724171.
162. Ordás CM, Cuadrado ML, Pareja JA, de-Las-Casas-Cámara G, Gómez-Vicente L, Torres-Gaona G, et al. (1 February 2020). "Transcutaneous Supraorbital Stimulation as a Preventive Treatment for Chronic Migraine: A Prospective, Open-Label Study". Pain Medicine (Malden, Mass.). 21 (2): 415–422. doi:10.1093/pm/pnz119. PMID   31131857.
163. Jenkins B (October 2020). "Migraine management". Australian Prescriber. 43 (5): 148–151. doi:10.18773/austprescr.2020.047. PMC   7572189 . PMID   33093740.
164. Mohanty D, Lippmann S (April 2020). "CGRP Inhibitors for Migraine". Innovations in Clinical Neuroscience. 17 (4–6): 39–40. PMC   7413335 . PMID   32802591.
165. Bland R, Levine T (5 April 2016). "Treatment of Status Migrainosus with Oral Dexamethasone in an Outpatient Setting (P1.160)" . Neurology. 86 (16_supplement) P1.160. doi:10.1212/WNL.86.16_supplement.P1.160.
166. Woldeamanuel Y, Rapoport A, Cowan R (2014). "What is the evidence for the use of corticosteroids in migraine?". Current Pain and Headache Reports. 18 (12) 464. doi:10.1007/s11916-014-0464-x. PMID   25373608.
167. Karlsson WK, Ostinelli EG, Zhuang ZA, Kokoti L, Christensen RH, Al-Khazali HM, et al. (18 September 2024). "Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis". BMJ (Clinical Research Ed.). 386 e080107. doi:10.1136/bmj-2024-080107. PMC   11409395 . PMID   39293828.
168. Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A (April 2024). "Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update". Headache. 64 (4): 333–341. doi: 10.1111/head.14692 . PMID   38466028.
169. Gibb V (26 April 2024). "American Headache Society Position Statement: Calcitonin Gene-Related Peptide (CGRP) Inhibitors should now be considered a first-line option for migraine prevention". Association of Migraine Disorders. Retrieved 5 November 2025.
170. Shao Q, Rascati KL, Lawson KA, Barner JC, Sonawane KB, Rousseau JF (November 2022). "Real-world opioid use among patients with migraine enrolled in US commercial insurance and risk factors associated with migraine progression". Journal of Managed Care & Specialty Pharmacy. 28 (11): 1272–1281. doi:10.18553/jmcp.2022.28.11.1272. PMC   10373005 . PMID   36282930.
171. "New Research Explores Migraine and Opioids". American Headache Society. Retrieved 23 November 2025.
172. Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, et al. (1 October 2021). "Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis". JAMA Network Open. 4 (10): e2128544. doi:10.1001/jamanetworkopen.2021.28544. PMC   8506232 . PMID   34633423.
173. "Migraine Information Page: Prognosis". National Institute for Neurological Disorders and Stroke (NINDS). National Institutes of Health (US). Archived from the original on 10 June 2020.
174. "Key facts and figures about migraine". The Migraine Trust. 2017. Archived from the original on 12 March 2017. Retrieved 13 June 2021.
175. "The Global Burden of Disease: 2004 Update" (PDF). World Health Organization. 2008. p. 33. Archived from the original (PDF) on 13 June 2021. Disability classes for the Global Burden of Disease study (table 8)
176. Brennan KC, Pietrobon D (March 2018). "A Systems Neuroscience Approach to Migraine". Neuron. 97 (5): 1004–1021. doi:10.1016/j.neuron.2018.01.029. PMC   6402597 . PMID   29518355.
177. Tana C, Onan D, Messina R, Waliszewska-Prosół M, Garcia-Azorin D, Leal-Vega L, et al. (August 2025). "From Headache to Heart Health: Investigating the Migraine-Cardiovascular Disease Connection". Neurology and Therapy. 14 (4): 1229–1268. doi:10.1007/s40120-025-00785-z. PMC   12255647 . PMID   40540097.
178. He Z, Zhang Q, Sun Y, Yang J, Zhao M (17 October 2025). "Migraine and risk of all-cause mortality and specific cause mortality: a systematic review and meta-analysis". The Journal of Headache and Pain. 26 (1): 223. doi: 10.1186/s10194-025-02164-3 . PMC   12534955 . PMID   41107723.
179. Jeong E, Mogos MF, Chen Y (12 June 2024). "Stroke Risk Reduction in Migraine Patients Using Propranolol: Evidence from Two Large-Scale Real-World Data Analyses". medRxiv   10.1101/2024.06.11.24308801 .
180. Stovner LJ, Zwart JA, Hagen K, Terwindt GM, Pascual J (April 2006). "Epidemiology of headache in Europe". European Journal of Neurology. 13 (4): 333–45. doi: 10.1111/j.1468-1331.2006.01184.x . PMID   16643310. S2CID   7490176.
181. Wang SJ (March 2003). "Epidemiology of migraine and other types of headache in Asia". Current Neurology and Neuroscience Reports. 3 (2): 104–8. doi:10.1007/s11910-003-0060-7. PMID   12583837. S2CID   24939546.
182. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. (May 2010). "Global prevalence of chronic migraine: a systematic review". Cephalalgia. 30 (5): 599–609. doi:10.1111/j.1468-2982.2009.01941.x. PMID   19614702. S2CID   5328642.
183. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, et al. (2012). "The cost of headache disorders in Europe: the Eurolight project". European Journal of Neurology. 19 (5): 703–711. doi:10.1111/j.1468-1331.2011.03612.x. ISSN   1351-5101.
184. Gooch CL, Pracht E, Borenstein AR (2017). "The burden of neurological disease in theUnited States: A summary report and call to action". Annals of Neurology. 81 (4): 479–484. doi:10.1002/ana.24897. ISSN   0364-5134. Archived from the original on 19 June 2025.
185. Stovner LJ, Andrée C (June 2008). "Impact of headache in Europe: a review for the Eurolight project". The Journal of Headache and Pain. 9 (3): 139–46. doi:10.1007/s10194-008-0038-6. PMC   2386850 . PMID   18418547.
186. Orr SL, Shapiro RE (2022). "The elephant in the room: How the underfunding of headache research stunts the field". Headache: The Journal of Head and Face Pain. 62 (9): 1234–1238. doi:10.1111/head.14396. ISSN   0017-8748.
187. Miller N (2005). Walsh and Hoyt's clinical neuro-ophthalmology (6 ed.). Philadelphia, Pa.: Lippincott Williams & Wilkins. p. 1275. ISBN   978-0-7817-4811-7. Archived from the original on 12 March 2017.
188. Liddell HG, Scott R. "ἡμικρανία". A Greek-English Lexicon. Archived from the original on 8 November 2013. on Perseus
189. Anderson K, Anderson LE, Glanze WD (1994). Mosby's Medical, Nursing & Allied Health Dictionary (4 ed.). Mosby. p. 998. ISBN   978-0-8151-6111-0.
190. Borsook D (2012). The migraine brain: imaging, structure, and function. New York: Oxford University Press. pp. 3–11. ISBN   978-0-19-975456-4. Archived from the original on 13 March 2017.
191. Waldman SD (2011). Pain management (2 ed.). Philadelphia, PA: Elsevier/Saunders. pp. 2122–2124. ISBN   978-1-4377-3603-8. Archived from the original on 23 August 2023. Retrieved 24 September 2016.
192. "Sex(ism), Drugs, and Migraines". Distillations. Science History Institute. 15 January 2019. Archived from the original on 14 March 2021. Retrieved 6 February 2020.
193. Margaret C, Simon M (2002). Human osteology: in archaeology and forensic science (Repr. ed.). Cambridge [etc.]: Cambridge University Press. p. 345. ISBN   978-0-521-69146-8. Archived from the original on 17 June 2013.
194. Colen C (2008). Neurosurgery. Colen Publishing. p. 1. ISBN   978-1-935345-03-9.
195. Daniel BT (2010). Migraine. Bloomington, IN: AuthorHouse. p. 101. ISBN   978-1-4490-6962-9. Archived from the original on 13 March 2017.
196. Butticè C (April 2022). What you need to know about headaches. Santa Barbara, California: ABC-CLIO/Bloomsbury. pp. 29–30. ISBN   978-1-4408-7531-1. OCLC   1259297708. Archived from the original on 28 November 2022. Retrieved 2 November 2022.
197. Tfelt-Hansen PC, Koehler PJ (May 2011). "One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010". Headache. 51 (5): 752–78. doi:10.1111/j.1526-4610.2011.01892.x. PMID   21521208. S2CID   31940152.
198. Tfelt-Hansen P, Koehler P (2008). "History of the Use of Ergotamine and Dihydroergotamine in Migraine from 1906 and Onward". Cephalalgia. 28 (8): 877–886. doi:10.1111/j.1468-2982.2008.01578.x. PMID   18460007.

Further reading

• Ashina M (November 2020). Ropper AH (ed.). "Migraine". The New England Journal of Medicine. 383 (19): 1866–1876. doi:10.1056/nejmra1915327. PMID   33211930. S2CID   227078662.
• Oskoui M, Pringsheim T, Billinghurst L, Potrebic S, Gersz EM, Gloss D, et al. (September 2019). "Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society". Neurology. 93 (11): 500–509. doi:10.1212/WNL.0000000000008105. PMC   6746206 . PMID   31413170.
• Oskoui M, Pringsheim T, Holler-Managan Y, Potrebic S, Billinghurst L, Gloss D, et al. (September 2019). "Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society". Neurology. 93 (11): 487–499. doi: 10.1212/WNL.0000000000008095 . PMID   31413171. S2CID   199662718.

External links

External audio
Sex(ism), Drugs, and Migraines, Distillations Podcast, Science History Institute, 15 January 2019